Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial To Evaluate The Safety And Immunogenicity Of The Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) From Instituto Butantan, In Adults And The Older Adults

This study aims to demonstrate the safety and immunogenicity of two formulations of the monovalent influenza vaccine candidate A (H5N8) (inactivated, fragmented, and adjuvanted with IB160) from the Instituto Butantan in adults and older adults, to be developed for situations of pandemic, epidemic or outbreak of avian type A/H5 in humans, in the context of pandemic preparedness.

Study Overview

• Status: Recruiting
• Conditions: Avian Influenza A Virus
• Intervention / Treatment: Biological: Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg; Biological: Monovalent influenza vaccine type A (H5N8) 15 mcg; Other: Placebo

Detailed Description

This is a clinical trial (randomized, double-blind, placebo-controlled Phase I/II) to evaluate the safety and immunogenicity of two formulations of the monovalent influenza vaccine candidate A (H5N8) (inactivated, fragmented, and adjuvanted with IB160) from the Instituto Butantan in adults and older adults. Safety will be assessed by the frequency (n, %) of participants with solicited (local and systemic) and unsolicited adverse events reported within 7 days post each vaccination; as well as the frequency of adverse reactions post causality evaluation. Immunogenicity will be assessed by seroprotection and seroconversion rates in the 21 days after the second dose.

• Study Type: Interventional
• Enrollment (Estimated): 700
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Brazil
  • São Paulo, Brazil, 05403-010
    • Not yet recruiting
    • Centro de Pesquisas Clínicas do Hospital das Clínicas da FMUSP
    • Contact: Ferdinando MD Menezes, PhD; Phone Number: (11)98373-2290; Email: f.menezes@hc.fm.usp.br
  • Minas Gerais
    • Belo Horizonte, Minas Gerais, Brazil, 30750-140
      • Not yet recruiting
      • Centro de Terapias Avançadas E Inovadoras - Ct Terapias/Ufmg
      • Contact: Mauro MD Teixeira, PhD; Phone Number: (31)2520-4008; Email: mmtex.ufmg@gmail.com
  • Pernambuco
    • Recife, Pernambuco, Brazil, 52011-040
      • Recruiting
      • Platano Centro De Pesquisa Clinica LTDA
      • Contact: Carlos MD Brito, PhD; Phone Number: (81)99127-7732; Email: cbritoc@gmail.com
  • São Paulo
    • Serrana, São Paulo, Brazil
      • Not yet recruiting
      • Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preta da Universidade de São Paulo - (Centro de Pesquisa Clínica - S)
      • Contact: Marcos MD Borges, PhD; Phone Number: (16)98116-5608; Email: marcosborges@fmrp.usp.br
    • São José do Rio Preto, São Paulo, Brazil, 15090-000
      • Not yet recruiting
      • Fundação Faculdade Regional de Medicina de São Jose do Rio Preto - (Centro integrado de Pesquisa CIP)
      • Contact: Mauricio MD Nogueira, PhD; Phone Number: (17)98811-0550; Email: mauricio.nogueira@edu.famerp.br

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Males and non-pregnant females aged ≥ 18 years at the time of the first study vaccination.
2. Be in good health and clinically stable (defined as having no pre-existing health condition or having a pre-existing health condition that has not required a change in treatment or hospitalization for worsening of disease in the 3 months prior to the date of the first study vaccination).
3. Agree to participate in the study and provide written informed consent prior to the initiation of any study procedures.
4. Be able and willing to comply with all study procedures, including completing Participant Diaries, collecting blood samples, and being available for scheduled study visits and contacts.
5. For females of childbearing potential, have a negative pregnancy test prior to the first study vaccination.
6. For women of childbearing potential, be willing to use effective contraceptive measures during the screening visit until at least 30 days after the second study vaccination.

Exclusion Criteria:

1. Having received any vaccine (including seasonal influenza) 28 days prior to the date of the first study vaccination or having any vaccination in the period from the first vaccination to the immune response assessment visit after the last vaccination.
2. Known hypersensitivity or allergy to eggs, chicken proteins, squalene-based adjuvants, or any other component of the investigational product.
3. History of serious adverse reaction or anaphylaxis to any previous influenza vaccine (licensed or not).
4. Having received any influenza A/H5 vaccine or history of exposure to avian influenza A/H5.
5. Presence of a bleeding disorder or any condition that contraindicates intramuscular injection.
6. Having received immunoglobulin, blood, or any blood-derived product in the 3 months prior to the date of the first study vaccination or having had immunoglobulin or blood-derived product administered during the entire follow-up of the study.
7. Having received a solid organ, bone marrow, or stem cell transplant.
8. Having a history of asplenia (anatomic or functional).
9. Having any confirmed or suspected immunosuppressive or immunodeficiency condition, including a history of human immunodeficiency virus (HIV) infection.
10. Having a history of Guillain-Barré syndrome or other demyelinating disease.
11. Having a history of neurological disease, seizures, or progressive or severe neurological disorder.
12. History of malignant neoplasm or previous history of malignant neoplasm being disease-free for 5 years at the date of the first study vaccination (with the exception of basal cell carcinoma of the skin), autoimmune disease (including type 1 diabetes mellitus), liver cirrhosis and renal failure.
13. History of significant, progressive or decompensated chronic disease in the 3 months prior to the date of the first study vaccination (complicated type 2 diabetes mellitus, liver disease, kidney disease, heart disease, advanced arteriosclerotic disease or lung disease such as oxygen-dependent chronic obstructive pulmonary disease, among others).
14. Having received or using radiotherapy, chemotherapy, cytotoxic drugs, immunosuppressants or immunomodulators in the 6 months prior to the date of the first study vaccination.
15. Use of systemic corticosteroids (oral or parenteral) in the 3 months prior to the date of the first study vaccination, at an immunosuppressive dose equivalent to a dose of ≥ 20 mg of prednisone per day for ≥ 14 days or a cumulative dose of ≥ 280 mg. Topical use of corticosteroids (e.g., cream, eye drops, inhalation and intranasal sprays) is permitted, within the dosage indicated on the product label.
16. Presenting a behavioral, cognitive disorder/disorder or psychiatric illness that, in the opinion of the Investigator, may interfere with the ability to participate in the study.
17. Infection with the human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
18. Abuse of alcohol or drugs in the 12 months prior to the date of the first study vaccination, that may interfere with the ability to participate in the study.
19. Body mass index (BMI) ≥ 35 kg/m2 on the date of the first study vaccination.
20. Clinically significant abnormalities in the general physical examination.
21. Major surgery or surgery with the use of general anaesthesia planned to occur in the period from the first vaccination to the visit to assess the immune response after the last vaccination.
22. Women who are pregnant, breastfeeding or planning to become pregnant during the 30 days after the last vaccination in the study.
23. Laboratory parameter values at the screening visit equal to or greater than grade 2 will be considered as a criterion for exclusion from participation in the study.
24. Presenting any clinically significant condition or situation that, in the opinion of the Investigator, represents a risk to the participant health or may interfere with the evaluation of the study objectives, the schedule of visits, participation in or completion of the study (such as planned travel or change of residence, among others).
25. Having participated in another clinical trial involving an experimental product, with less than three months between the completion of that follow-up and the planned date of the first vaccination in this study, or plans to enter a clinical study during the period of this study.
26. Institutionalized individual (people residing in long-term care, assistance or health care institutions and deprived of liberty).

aa. Being related to or part of the research centre staff or employee directly involved in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Monovalent Influenza Vaccine A (H5N8) 7.5 mcg; Intervention: Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) from Instituto Butantan, containing 7.5 mcg/dose of hemagglutinin (HA) and adjuvant IB160 (0.5 mL/dose of final combined product).	Biological: Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg; Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg + IB160 adjuvant (0.5mL total); Other Names: Avian Flu vaccine
Experimental: Monovalent influenza vaccine A (H5N8) 15 mcg; Intervention: Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) from Instituto Butantan, containing 15 mcg/dose of hemagglutinin (HA) and adjuvant IB160 (0.5 mL/dose of final combined product).	Biological: Monovalent influenza vaccine type A (H5N8) 15 mcg; Monovalent influenza vaccine type A (H5N8) 15 mcg + IB160 adjuvant (0.5mL total); Other Names: Avian Flu vaccine
Placebo Comparator: Placebo; Phosphate buffered saline (PBS) (0.5 mL/dose).	Other: Placebo; Phosphate buffered saline (PBS) (0.5 mL/dose).; Other Names: Control arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety - Percentage of participants with solicited and unsolicited adverse events	Percentage (%) of participants with solicited (local and systemic) and unsolicited adverse events, for each intervention group, in adults and older adults.	7 days post each vaccination.
Safety - Percentage of solicited and unsolicited adverse events by intensity degree	Percentage of solicited and unsolicited adverse events by intensity degree for each intervention group, in adults and older adults.	7 days post each vaccination
Safety - Percentage of participants with solicited and unsolicited adverse reactions	Percentage of participants with solicited and unsolicited adverse reactions, for each intervention group, in adults and older adults.	7 days post each vaccination
Safety - Percentage of solicited and unsolicited adverse reactions by intensity degree	Percentage of solicited and unsolicited adverse reactions by intensity degree for each intervention group, in adults and older adults.	7 days post each vaccination
Safety - Description of solicited adverse reactions, regarding duration, time until onset and use of medication	Description of solicited adverse reactions, regarding duration, time until onset and use of medication, for each intervention group, in adults and older adults.	7 days post each vaccination
Immunogenicity - Seroconversion rate post second vaccination	Seroconversion rate after the second vaccination (by the hemagglutination inhibition test - HI), for each intervention group, in adults and older adults.	21 days post second vaccination
Immunogenicity - Seroprotection rate post second vaccination	Seroprotection rate after the second vaccination (by the hemagglutination inhibition test - HI), for each intervention group, in adults and older adults.	21 days post second vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety - Percentage of participants with unsolicited adverse events	Percentage of participants with unsolicited adverse events, for each intervention group, in adults and older adults.	21 days post each vaccination
Safety - Percentage and intensity of unsolicited adverse events	Percentage and intensity of unsolicited adverse events, for each intervention group, in adults and older adults.	21 days post each vaccination
Safety - Percentage of participants with unsolicited adverse reactions	Percentage of participants with unsolicited adverse reactions, for each intervention group, in adults and older adults.	21 days post each vaccination
Safety - Percentage and intensity of unsolicited adverse reactions	Percentage and intensity of unsolicited adverse reactions,, for each intervention group, in adults and older adults.	21 days post second vaccination
Percentage of participants with adverse events of special interest (AEI)	Percentage of participants with adverse events of special interest (AEI), for each intervention group, in adults and older adults.	the entire follow-up of the study (6 months)
Safety - Percentage and intensity of the participants with adverse events of special interest (AEI)	Percentage and intensity of the participants with adverse events of special interest (AEI), for each intervention group, in adults and older adults.	The entire follow-up of the study (6 months)
Safety - Percentage of participants with serious adverse events (SAE)	Percentage of participants with serious adverse events (SAE), for each intervention group, in adults and older adults.	Entire follow-up of the study (6 months)
Safety - Percentage and intensity of serious adverse events (SAE)	Percentage and intensity of serious adverse events (SAE), for each intervention group, in adults and older adults.	entire follow-up of the study (6 months)
Immunogenicity - Ratio between the Geometric Mean Titers (rGMT) of antibodies	Ratio between the Geometric Mean Titers (rGMT) of antibodies compared to that of pre-vaccination (by the hemagglutination inhibition test - HI), for each intervention group, in adults and older adults.	21 days post the first vaccination
Immunogenicity - Ratio between the Geometric Mean Titers (rGMT) of antibodies	Ratio of the Geometric Mean Titers (rGMT) of antibodies, post second vaccination about that of pre-vaccination (by the hemagglutination inhibition test - HI), for each intervention group, in adults and older adults.	21 days post the second vaccination
Immunogenicity - Seroconversion rate	Seroconversion rate (by the hemagglutination inhibition test - HI), for each intervention group, in adults and older adults.	21 days post the first vaccination
Immunogenicity - Geometric Mean Titers (GMT)	Geometric Mean Titers (GMT) pre and post-vaccination (by the hemagglutination inhibition test - HI), for each intervention group, in adults and older adults.	pre-vaccination, 21 days post the first vaccination and 21 days post the second vaccination.
Immunogenicity - Seroprotection rate	Seroprotection rate pre and post-vaccination (by the hemagglutination inhibition test - HI), for each intervention group, in adults and older adults.	pre-vaccination and 21 days post first vaccination
Immunogenicity - Ratio between the Geometric Mean Titers (rGMT) of antibodies	Ratio between the Geometric Mean Titers (rGMT) of antibodies, pre and post-vaccination (by microneutralization test - MN), for each intervention group, in adults and older adults.	21 days post the first vaccination
Immunogenicity - Ratio between the Geometric Mean Titers (rGMT) of antibodies	Ratio between the Geometric Mean Titers (rGMT) of antibodies, pre and post-vaccination (by microneutralization test - MN), for each intervention group, in adults and older adults.	21 days post the second vaccination
Immunogenicity - Seroconversion rate pre and post vaccination	Seroconversion rate 21 days post the first vaccination and 21 days post the second vaccination (by microneutralization test - MN), for each intervention group, in adults and older adults.	21 days post the first vaccination and 21 days post the second vaccination.
Immunogenicity - Seroprotection rate pre and post-vaccination	Seroprotection rate pre-vaccination, 21 days after the first vaccination and 21 days after the second vaccination (by microneutralization test - MN), for each intervention group, in adults and older adults.	pre-vaccination, 21 days post the first vaccination and 21 days post the second vaccination
Immunogenicity - Geometric Mean Titers (GMT) pre and post-vaccination	Geometric Mean Titers (GMT) pre vaccination, 21 days post the first vaccination and 21 days after the second vaccination (by the microneutralization test - MN), for each intervention group, in adults and older adults.	pre vaccination, 21 days post the first vaccination and 21 days post the second vaccination.
Immunogenicity - Estimation of rGMT between the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) containing 7.5 mcg of HA/dose compared to that containing 15 mcg of HA/dose	Estimation of rGMT between the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) containing 7.5 mcg of HA/dose compared to that containing 15 mcg of HA/dose (by the hemagglutination inhibition test - HI)	21 days post the second vaccination

Collaborators and Investigators

• Sponsor: Butantan Institute
• Collaborators: Butantan Foundation

Publications and helpful links

General Publications

• Akamatsu MA, Sakihara VA, Carvalho BP, de Paiva Abrantes A, Takano MAS, Adami EA, Yonehara FS, Dos Santos Carneiro P, Rico S, Schanoski A, Meros M, Simpson A, Phan T, Fox CB, Ho PL. Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil. PLoS One. 2020 Jun 3;15(6):e0233632. doi: 10.1371/journal.pone.0233632. eCollection 2020.
• Francis DP, Du YP, Precioso AR. Global vaccine supply. The increasing role of manufacturers from middle income countries. Vaccine. 2014 Sep 15;32(41):5259-65. doi: 10.1016/j.vaccine.2014.07.069. Epub 2014 Aug 8.
• Miyaki C, Meros M, Precioso AR, Raw I. Influenza vaccine production for Brazil: a classic example of successful North-South bilateral technology transfer. Vaccine. 2011 Jul 1;29 Suppl 1:A12-5. doi: 10.1016/j.vaccine.2011.04.127.
• Vanni T, Thome BC, Sparrow E, Friede M, Fox CB, Beckmann AM, Huynh C, Mondini G, Silveira DH, Viscondi JYK, Braga PE, Silva AD, Salomao MDG, Piorelli RO, Santos JP, Gattas VL, Lucchesi MBB, Oliveira MMM, Koike ME, Kallas EG, Campos LMA, Coelho EB, Siqueira MAM, Garcia CC, Miranda MD, Paiva TM, Timenetsky MDCST, Adami EA, Akamatsu MA, Ho PL, Precioso AR. Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial. PLoS One. 2022 Oct 18;17(10):e0274943. doi: 10.1371/journal.pone.0274943. eCollection 2022.

Study record dates

Study Major Dates

• Study Start (Actual): September 10, 2025
• Primary Completion (Estimated): August 10, 2027
• Study Completion (Estimated): October 10, 2027

Study Registration Dates

• First Submitted: February 14, 2025
• First Submitted That Met QC Criteria: February 19, 2025
• First Posted (Actual): February 24, 2025

Study Record Updates

• Last Update Posted (Actual): April 2, 2026
• Last Update Submitted That Met QC Criteria: April 1, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Safety; Immunogenicity; Avian Influenza; Influenza A Virus Subtype H5N8
• Additional Relevant MeSH Terms: Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Animal Diseases; Bird Diseases; Influenza in Birds; Substandard Drugs; Pharmaceutical Preparations; Counterfeit Drugs
• Other Study ID Numbers: FLP-02-IB

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No